医学
部分凝血活酶时间
止血
甲状腺
凝结
亚临床感染
凝血酶原时间
甲状腺疾病
血管性血友病
凝血障碍
内科学
胃肠病学
血管性血友病因子
血小板
外科
混凝试验
作者
Massimo Franchini,Chiara Zugni,Dino Veneri,Giorgio Gandini,Giuseppe Lippi,Franco Manzato,Paolo Brazzarola
出处
期刊:PubMed
日期:2004-11-01
卷期号:89 (11): 1341-6
被引量:27
摘要
Various coagulation abnormalities occur in patients with thyroid diseases. These abnormalities range from subclinical laboratory findings to hemorrhage or thromboembolism. However, the prevalence of hemostatic abnormalities in patients with thyroid diseases is still unclear.Between January 1999 and December 2003, 1342 consecutive patients with various thyroid diseases who were candidates for thyroid surgery underwent preoperative screening of hemostatic parameters including prothrombin time, activated partial thromboplastin time and platelet-related hemostasis with the PFA-100 platelet-function analyzer.Thirty-nine patients (2.9%) had abnormalities of the coagulation screening tests. Of these, 35 patients had von Willebrand's disease (type 1 in 33 cases and type 2A in 2 cases), 2 patients had decreased platelet aggregability, and 2 patients had coagulation factor XI deficiency. As all patients with coagulation abnormalities responded to subcutaneous desmopressin injection (0.3 microg/Kg BW), this drug was successfully used as surgical prophylaxis.Up to 3% of patients with thyroid diseases undergoing thyroid surgery have coagulation abnormalities, in most cases resembling von Willebrand's disease. Coagulation screening tests are needed in order to identify those patients at increased risk of bleeding.
科研通智能强力驱动
Strongly Powered by AbleSci AI